mRNA therapy REP-0003 aims to reverse plaque in homozygous familial hypercholesterolemia
Louis shares a note that Repair Biotechnologies' investigational mRNA therapy REP-0003 received FDA eligibility under the Rare Disease Evidence Principles Pathway for homozygous familial hypercholesterolemia. It aims to remove intracellular cholesterol rather than lower LDL.



